Sales rose 1.2% year-on-year to 883 million yen, operating loss of 943 million yen, ordinary income of 108 million yen, quarterly net loss attributable to owners of the parent of 11 million yen. Segments report trends for Pharmaceuticals, LAL, Raw Materials, and Royalties. Full-year forecast for 2027 unchanged.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4548","jir_company_name":"Biochemical Industry Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4548-20260805-01.pdf","jir_short_summary":"Sales rose 1.2% year-on-year to 883 million yen, operating loss of 943 million yen, ordinary income of 108 million yen, quarterly net loss attributable to owners of the parent of 11 million yen. Segments report trends for Pharmaceuticals, LAL, Raw Materials, and Royalties. Full-year forecast for 2027 unchanged.","jir_summary":"### Overview of Results\nFor the first quarter cumulative period, sales were 8,833 million yen, up 1.2% YoY, remaining solid, but operating loss occurred due to higher manufacturing costs. Ordinary income was 108 million yen in positive territory, but quarterly net loss attributable to owners of the parent was 11 million yen. The pharmaceutical business faced declines in overseas drugs, while the LAL business contributed with favorable performance. Segment-wise, Pharmaceuticals and LAL comprised the majority of the total.\n\n### Financial Position and Outlook\nTotal assets were 84,490 million yen, liabilities 10,300 million yen, and net assets 74,189 million yen. Decreases in cash, deposits, and marketable securities affected figures. There were no changes to the consolidated full-year earnings forecast announced in May 2026, and the full-year outlook remains unchanged. Supplemental earnings materials have been disclosed. Going forward, R&D will continue to focus on new drug development and advancing alliances in the carbohydrate science field.","jir_financial_highlights":"Sales: 8,833 million yen (YoY +1.2%)\nOperating loss: \u25b3943 million yen (YoY previous period \u25b3365 million yen)\nOrdinary income: 108 million yen (YoY previous period \u25b3132 million yen)\nNet income attributable to owners of the parent: \u25b311 million yen (YoY previous period \u25b3200 million yen)\nTotal assets: 84,490 million yen (YoY end of previous term \u25b31,854 million yen)\nEquity ratio: 87.8% (YoY end of previous term +0.6pp)","jir_category":"","jir_hashtags":"#BiochemicalIndustryCo.,Ltd., #financial_summary, #JapanStocks","jir_key_figures":"Sales: 8,833 million yen\nOperating loss: \u25b3943 million yen\nOrdinary income: 108 million yen\nNet income attributable to owners of the parent: \u25b311 million yen\nTotal assets: 84,490 million yen\nEquity ratio: 87.8%","jir_meta_title":"\u3010Biochemical Industry Co.,Ltd.\u3011Q1 FY2027 Consolidated Results Summary | Sales 8,833 million yen; Net loss 11 million yen","jir_meta_description":"Summary of Biochemical Industry's Q1 FY2027 consolidated financial results. Sales rose 1.2% YoY to 883 million yen, operating loss 943 million yen, ordinary income 108 million yen, net loss 11 million yen. Segment trends and outlook.","jir_og_title":"Biochemical Industry Co.,Ltd. | Q1 FY2027 Consolidated Results Summary","jir_og_description":"Q1 sales increased but operating loss incurred. Ordinary income turned positive; full-year forecast remains unchanged. Explanations of LAL\/overseas drug trends and R&D policy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":56853,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-95882","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n